Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Gross Margin (2016 - 2026)

United Therapeutics' Gross Margin history spans 17 years, with the latest figure at 86.91% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 277.0% to 86.91% in Q4 2025 year-over-year; TTM through Dec 2025 was 87.92%, a 131.0% decrease, with the full-year FY2025 number at 87.92%, down 131.0% from a year prior.
  • Gross Margin hit 86.91% in Q4 2025 for United Therapeutics, down from 87.38% in the prior quarter.
  • Over the last five years, Gross Margin for UTHR hit a ceiling of 94.39% in Q1 2022 and a floor of 86.91% in Q4 2025.
  • Historically, Gross Margin has averaged 90.22% across 5 years, with a median of 89.25% in 2023.
  • Biggest five-year swings in Gross Margin: surged 197bps in 2022 and later tumbled -471bps in 2023.
  • Tracing UTHR's Gross Margin over 5 years: stood at 91.67% in 2021, then dropped by -4bps to 88.04% in 2022, then rose by 0bps to 88.45% in 2023, then rose by 1bps to 89.69% in 2024, then decreased by -3bps to 86.91% in 2025.
  • Business Quant data shows Gross Margin for UTHR at 86.91% in Q4 2025, 87.38% in Q3 2025, and 89.03% in Q2 2025.